



## Hikma Pharmaceuticals PLC

### Voting Results of 2016 Annual General Meeting

LONDON, 12 May 2016 – Hikma Pharmaceuticals PLC (the “**Company**”) announces its Annual General Meeting (“**AGM**”), held at The Westbury, Bond Street, Mayfair, London W1S 2YF on 12 May 2016 commenced at 11:00 am today. All resolutions were duly passed by shareholders by way of a poll. Resolutions 1 to 16 were passed as ordinary resolutions and Resolutions 17 to 19 were passed as special resolutions.

As previously announced, Mr. Breffni Byrne retired from the Board at the close of the AGM.

Copies of the resolutions dealing with special business passed at the AGM have been submitted to the UK Listing Authority for publication through the Listing Authority’s Document Viewing Facility.

The total number of votes cast on the poll for each resolution (the full text of the resolutions is detailed in the notice of the AGM dated 7 April 2016) is set out below. The number of Ordinary Shares in issue on 12 May 2016 was 239,385,501.

	<b>Resolution</b>	<b>Votes For</b>	<b>%</b>	<b>Votes Against</b>	<b>%</b>	<b>Votes Withheld</b>
1	To receive the 2015 report and accounts	201,043,426	99.83%	347,462	0.17%	197,375
2	To approve a final dividend of 21 cents per share	201,588,263	100.00%	0	0.00%	0
3	Appoint PricewaterhouseCoopers LLP as auditors	198,964,787	98.70%	2,623,476	1.30%	0
4	Authorise the Audit Committee to set the remuneration of the auditors	194,789,399	96.63%	6,798,864	3.37%	0
5	Appoint Jochen Gann	199,061,688	98.75%	2,526,551	1.25%	0
6	Appoint John Castellani	200,675,819	99.55%	912,421	0.45%	0
7	Reappointment of Said Darwazah	196,614,743	97.69%	4,641,117	2.31%	332,378
8	Reappointment of Mazen Darwazah	197,410,765	97.93%	4,177,474	2.07%	0
9	Reappointment of Robert Pickering	199,988,353	99.21%	1,599,886	0.79%	0
10	Reappointment of Ali Al Husry	199,090,927	98.76%	2,497,312	1.24%	0
11	Reappointment of Michael Ashton	196,521,848	98.45%	3,095,916	1.55%	1,970,475
12	Reappointment of Ronald Goode	198,210,008	99.05%	1,901,133	0.95%	1,477,098

	<b>Resolution</b>	<b>Votes For</b>	<b>%</b>	<b>Votes Against</b>	<b>%</b>	<b>Votes Withheld</b>
13	Reappointment of Patrick Butler	200,562,012	99.49%	1,026,227	0.51%	0
14	Reappointment of Dr Pamela Kirby	199,880,568	99.15%	1,707,671	0.85%	0
15	Approve the 2015 remuneration implementation	173,423,087	88.97%	21,510,812	11.03%	6,654,338
16	Authorise the directors to allot shares	176,261,935	87.65%	24,841,433	12.35%	484,894
17	Disapply pre-emption rights	179,904,929	90.65%	18,558,726	9.35%	3,124,607
18	Authorise the company to buy back shares	200,673,199	99.55%	915,063	0.45%	0
19	Authorise the company to call general meetings on 14 days' notice	185,097,715	91.88%	16,365,074	8.12%	125,473

### **Declaration of final dividend**

The dividend of 21 cents per share will be paid on 19 May 2016 to shareholders on the register on 8 April 2016. Shareholders who are not resident in Jordan have been given the option of receiving their dividend in Pounds Sterling. The exchange rate in respect of this dividend will be \$1.4510 to £1. The exchange rate for Jordanian Dinar is fixed to the US Dollar at 1JD to \$1.4104.

**- ENDS -**

### **Enquiries:**

#### **Hikma Pharmaceuticals PLC**

Peter Speirs  
Company Secretary

+44 20 7399 2670

Susan Ringdal  
VP for Investor Relations and Strategy

+44 20 7399 2670

### **About Hikma**

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2015, Hikma achieved revenues of \$1,440 million and profit attributable to shareholders of \$252 million.